市場調査レポート
商品コード
1304547
同種幹細胞の世界市場-2023年~2030年Global Allogeneic Stem Cells Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
同種幹細胞の世界市場-2023年~2030年 |
出版日: 2023年07月07日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
同種幹細胞の世界市場規模は2022年に9億米ドルに達し、2030年には20億米ドルに達する好成長が予測されています。世界の同種幹細胞市場は、予測期間中(2023-2030年)にCAGR 9.6%を示すと予測されます。進行中の臨床試験や共同研究が同種幹細胞市場の動向を牽引し、需要を押し上げています。
同種幹細胞市場は近年著しい成長と開拓を遂げています。同種幹細胞は様々な細胞に分化する可能性があり、様々な慢性疾患や病態の治療に大きな期待が寄せられています。加えて、個別化医療に対する需要の高まりや、幹細胞研究に対する政府からの資金援助や支援があることも、市場の拡大に寄与しています。
世界の同種幹細胞市場は、心血管疾患、がん疾患、その他の慢性疾患の有病率の増加、幹細胞治療に対する認識と受容の高まり、同種幹細胞に関する研究開発活動の活発化、再生医療に対する需要の高まり、同種幹細胞移植の技術的進歩などの要因によって牽引されています。
心血管障害、神経変性疾患、整形外科的損傷、自己免疫疾患などの慢性疾患の有病率は世界的に上昇傾向にあります。同種幹細胞治療を含む再生医療は、これらの困難な疾患に対する革新的で有望な治療選択肢を提供し、このような先進的治療に対する需要を牽引しています。
幹細胞研究や組織工学技術の急速な進歩により、幹細胞生物学に対する理解や効果的な再生治療法の開発は著しく向上しています。このような技術革新は同種幹細胞の可能性と応用範囲を広げ、市場の成長に貢献しています。
例えば、2022年09月06日、食品医薬品局(FDA)によると、再生医療治療とは、試験管内で同種幹細胞由来の細胞を新しい生体材料で3Dプリントした足場です。スキャフォールドは、複数の種類の細胞を一つのインプラント上で増殖させ、組織の成長を加速させる。
幹細胞療法は、再生医療、腫瘍学、神経学、心臓学、整形外科学など、さまざまな分野で有望な成果をもたらしています。臨床試験や実際のエビデンスにより、幹細胞は損傷した組織を再生し、治癒を促進し、免疫系を調整し、これまで治療不可能であった病態に新たなアプローチを提供する可能性があることが実証されています。肯定的な治療結果が広く知られるようになるにつれて、幹細胞治療が広く受け入れられるようになっています。
ヘルスケアプロバイダーや医師の間で幹細胞治療が受け入れられていることも、市場の成長を促進する上で極めて重要です。医療従事者が幹細胞治療の安全性、有効性、そして適切な使用方法について自信を深めるにつれ、これらの治療を推奨し、診療に取り入れる可能性が高まる。ヘルスケアプロバイダーによる幹細胞治療の普及は、患者にとって幹細胞治療への幅広いアクセスにつながります。
高額な価格設定は、治療の選択肢として同種幹細胞移植を必要とする患者にとって、アクセスの障壁となります。ドナーのマッチング、移植前のコンディショニング、移植プロセス、移植後のケア、フォローアップなど、この治療法には多額の費用がかかるため、特にヘルスケア資源が限られている地域や保険適用が不十分な地域では、多くの患者にとって経済的に実現不可能な治療法となっています。
厳しい価格設定は、同種幹細胞移植の分野における研究開発への投資全体に影響を与える可能性があります。製薬会社、バイオテクノロジー企業、学術機関は、研究資金や研究実施、革新的な治療法の開発、この分野の発展において困難に直面する可能性があります。これは新たな治療法の開発を遅らせ、市場の拡大を制限します。
COVID-19パンデミックは同種幹細胞市場に大きな影響を与えました。パンデミックは同種幹細胞の収集、加工、輸送を含む世界なサプライチェーンを混乱させました。渡航の制限、社会的隔離措置、戸締まりなどは、ドナー細胞の入手や幹細胞製品の輸送に影響を与えました。このようなサプライチェーンの混乱は、治療の遅れにつながり、同種幹細胞移植へのアクセシビリティを低下させています。
様々な適応症に対する同種幹細胞移植を研究している現在進行中の臨床試験の多くも、パンデミックの影響を受けています。臨床試験への登録は困難であり、参加者やヘルスケア関係者の安全を確保するために一時的に中止されたり、変更されたりした試験もあります。このような臨床研究の中断は、新たな治療法の開発と商業化を遅らせる可能性があります。
ロシアとウクライナの紛争は、世界の同種幹細胞市場に中程度の影響を与えると推定されます。紛争は同種幹細胞のサプライチェーンを混乱させる可能性があり、特に輸送ルートが制限されたり、影響を受けた地域のヘルスケアインフラに混乱が生じたりした場合に影響が大きいです。この混乱はドナー細胞の入手の遅れや不足を招き、移植手術や市場全体の供給に影響を及ぼす可能性があります。
The Global Allogeneic Stem Cells Market size reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.0 billion by 2030. The global allogeneic stem cells market is expected to exhibit a CAGR of 9.6% during the forecast period (2023-2030). The ongoing clinical trials and collaborations are driving up demand for allogeneic stem cells market trends.
The allogeneic stem cells market has witnessed significant growth and development in recent years. Allogeneic stem cells have the potential to differentiate into various cell types and hold great promise for treating a wide range of chronic diseases and conditions. Additionally, the rising demand for personalized medicine and the availability of government funding and support for stem cell research are contributing to the market's expansion.
The global allogeneic stem cells market is driven by the factors such as the increasing prevalence of cardiovascular disorders, cancer diseases, and other chronic disorders, increasing awareness and acceptance of stem cell therapies, increasing research and development activities on allogeneic stem cells, rising demand for regenerative medicines, and technological advancements in allogeneic stem cell transplantation.
The prevalence of chronic diseases, such as cardiovascular disorders, neurodegenerative conditions, orthopedic injuries, and autoimmune diseases, is on the rise globally. Regenerative medicine, including allogeneic stem cell therapies, offers innovative and promising treatment options for these challenging conditions, driving the demand for such advanced therapies.
Rapid advancements in stem cell research and tissue engineering technologies have significantly enhanced the understanding of stem cell biology and the development of effective regenerative therapies. These technological breakthroughs have expanded the possibilities and applications of allogeneic stem cells, contributing to the market's growth.
For instance, on September 06, 2022, according to the Food and Drug Administration (FDA), a regenerative medicine therapy is a 3D-printed scaffold made of a new biomaterial with cells derived from allogeneic stem cells in vitro. Scaffolds allow multiple cell types to grow on a single implant to speed up tissue growth.
Stem cell therapies offer promising outcomes in various fields, including regenerative medicine, oncology, neurology, cardiology, and orthopedics. Clinical trials and real-world evidence have demonstrated the potential of stem cells to regenerate damaged tissues, promote healing, modulate the immune system, and provide novel approaches to treating previously incurable conditions. As positive treatment outcomes become more widely known, the acceptance of stem cell therapies grows.
The acceptance of stem cell therapies among healthcare providers and physicians is also crucial in driving market growth. As medical professionals gain confidence in the safety, efficacy, and appropriate use of stem cell therapies, they are more likely to recommend and incorporate these treatments into their practice. Increased adoption by healthcare providers leads to broader access to stem cell therapies for patients.
High pricing creates barriers to access for patients who may require allogeneic stem cell transplantation as a treatment option. The cost-intensive nature of the procedure, including donor matching, pre-transplant conditioning, transplantation process, post-transplant care, and follow-up, can make it financially unattainable for many individuals, especially in regions with limited healthcare resources or inadequate insurance coverage.
Stringent pricing can impact the overall investment in research and development in the field of allogeneic stem cell transplantation. Pharmaceutical companies, biotechnology firms, and academic institutions may face challenges in funding and conducting research, developing innovative therapies, and advancing the field. This slows down the development of new treatment options and limit the expansion of the market.
The COVID-19 pandemic significantly impacted the allogeneic stem cells market. The pandemic has disrupted global supply chains, including the collection, processing, and transportation of allogeneic stem cells. Restrictions on travel, social distancing measures, and lockdowns have affected the availability of donor cells and the transportation of stem cell products. This disruption in the supply chain has led to delays in treatments and reduced accessibility to allogeneic stem cell transplantation.
Many ongoing clinical trials investigating the use of allogeneic stem cells for various indications have been affected by the pandemic. Enrollment in trials has been challenging, and some trials have been temporarily halted or modified to ensure the safety of participants and healthcare personnel. These disruptions in clinical research may delay the development and commercialization of new therapies.
The Russia-Ukraine conflict is estimated to have a moderate impact on the global allogeneic stem cells market. The conflict can disrupt the supply chain of allogeneic stem cells, particularly if there are restrictions on transportation routes or disruptions in the healthcare infrastructure in the affected regions. This disruption can lead to delays or shortages in the availability of donor cells, affecting the transplantation procedures and overall market supply.
The global allogeneic stem cells market is segmented based on product, cell origin, application, and region.
The collection of cord blood is a safe and non-invasive procedure that poses no risk to the mother or newborn. This collection process occurs immediately after childbirth, and the storage of cord blood does not involve any ethical concerns. These factors make cord blood collection more acceptable and preferred by parents, leading to a significant supply of cord blood for therapeutic use.
Cord blood stem cells have demonstrated successful clinical outcomes in hematopoietic stem cell transplantation for various hematological disorders, including leukemia, lymphoma, and inherited metabolic disorders. The well-established use of cord blood in these therapeutic areas has solidified its position as a preferred source for allogeneic stem cell transplantation.
For instance, on August 29, 2022, StemCyte, a Southern California cord blood regenerative therapeutics company received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years.
North America hosts several major players in the field of allogeneic stem cells. Pharmaceutical companies, biotechnology firms, and stem cell banks based in North America have made significant investments in research, development, and commercialization of stem cell therapies. Their expertise, resources, and market presence contribute to the growth and dominance of the region in the allogeneic stem cells market.
For instance, on April 26, 2023, CELL Technologies Inc., a clinical-stage biopharmaceutical company announces the submission of the clinical data of its stem cell program in pain for Health Canada approval. CELL is aiming to become the first regulatory-approved stem cell provider in North America. CELL submitted clinical data from 3 studies on Arthritis, degenerative disc disease, and back pain.
North America, particularly the United States, has a robust and advanced healthcare infrastructure. The region boasts a network of renowned hospitals, research institutions, and specialized healthcare facilities that support the development, manufacturing, and delivery of allogeneic stem cell therapies. The presence of state-of-the-art healthcare facilities enables efficient clinical trials, patient access to treatment, and the integration of stem cell therapies into standard medical practice.
The major global players in the allogeneic stem cells market include: STEMCELL Technologies Inc., Lineage Cell Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Biosolution Co. Ltd., Cynata Therapeutics Ltd., JCR Pharmaceuticals Co. Ltd., MEDIPOST Co. Ltd., MiMedx Group Inc., Osiris Therapeutics Inc., and Stempeutics Research Pvt. Ltd.
The global allogeneic stem cells market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Australia
LIST NOT EXHAUSTIVE